0001104659-23-064694.txt : 20230628 0001104659-23-064694.hdr.sgml : 20230628 20230525170017 ACCESSION NUMBER: 0001104659-23-064694 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20230525 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BELITE BIO, INC CENTRAL INDEX KEY: 0001889109 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 12750 HIGH BLUFF DRIVE SUITE 475 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 858-246-6240 MAIL ADDRESS: STREET 1: 12750 HIGH BLUFF DRIVE SUITE 475 CITY: SAN DIEGO STATE: CA ZIP: 92130 CORRESP 1 filename1.htm

May 25, 2023

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

Attention: Tyler Howes

Re:          BELITE BIO, INC.

Registration Statement on Form F-3

Filed May 22, 2023

File No. 333-272125

Ladies and Gentlemen:

Pursuant to Rules 460 and 461 of the Rules and Regulations of the U.S. Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended, Belite Bio, Inc (the “Company”), hereby requests that the effectiveness of the above-referenced Registration Statement on Form F-3 (the “Registration Statement”) be accelerated to, and that the Registration Statement become effective at, 9:00 AM (Eastern time) on May 30, 2023, or as soon thereafter as practicable.

Once the Registration Statement has been declared effective, please orally confirm that event with Robert Plesnarski (+1 (202) 383-5149) or Portia Ku (+1 (212) 326-2168) of O’Melveny & Myers LLP, counsel to the Company. Thank you for your assistance with this matter.

[Signature page follows]

	Very truly yours,

	BELITE BIO, INC

	By:	/s/ Yu-Hsin Lin
	Name: Yu-Hsin Lin
	Title: Chief Executive Officer and Chairman